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Abstract: Inflammatory bowel disease (IBD) is an idiopathic disorder characterized by 
chronic abdominal pain and, on occasion, organ pathology. It is initiated by a traumatic 
insult inducing acute colitis, i.e., colon inflammation, and, over time, develops into a 
chronic condition due to failure of the inflammatory cascade to self-regulate correctly. 
The etiologies of inflammatory bowel disease are poorly understood and pain 
management therapies are limited, so this work attempted to gain a deeper understanding 
of methods that may potentially affect current practices in the treatment of IBD. A key 
feature of IBD is the large increase in immune cells, granulocytes, and pro-inflammatory 
cytokines, which results in an expansion of the submucosal area. This project was born 
out of a desire to better understand the neurogenic component of the inflammatory 
process in 2,4,6-trinitrobenzene sulfonic acid (TNBS) -induced colitis. TNBS, dissolved 
in ethanol, is delivered by intracolonic infusion and the epithelial mucosal barrier is 
compromised over time producing a diffuse inflammation in the distal colon 
characterized by ulceration, edema, leukocyte infiltration, and pro-inflammatory cytokine 
production. Because 6-diazo-5-oxo-l-norleucine (DON), a glutaminase (GLS) inhibitor, 
is known to reduce neurogenic inflammation in a somatic model of inflammation, we 
hypothesized that colonic administration of DON prior to induction of TNBS colitis will 
reduce inflammation in the rat colon. We specifically aimed at evaluating the anti-
inflammatory effect of DON in a colon that has received TNBS, determining its 
protective properties by analyzing TNBS-induced leukocyte infiltration, maintenance of 
epithelial integrity, and preservation of nerve fiber interaction with the lamina propria. 
Lastly, we studied the ability of DON to attenuate the increase in pro-inflammatory 
mediator mRNA during TNBS-induced colitis. Based on our results we accept our 
hypothesis, as we saw a decrease in edema, pro-inflammatory cell infiltration, and 
epithelial damage in colons that had been pre-treated with DON.
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According to the International Association for the Study of Pain, "Pain is an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage" (Bonica, 1979). Pain is an important system that 
alerts the body to the presence of injury. Pain and accompanying reflex withdrawal, 
autonomic, and affective responses, make up the nociceptive reaction (Woolf and Ma, 
2007). This reaction is generated by nociceptors which detect any stimuli that “in 
continuing to act would injure [the skin] still further” (Sherrington, 1903). 
One subtype of pain is inflammatory pain, which occurs after an insult to the body has 
occurred. It usually is accompanied by heat, redness, and swelling, all characteristic 
symptoms of inflammation. These responses function to promote healing of injured tissue 
and to protect the injured area while healing is underway by causing a guarding reflex to 
minimize external contact. This occurs in somatic and visceral inflammation, such as 




Dorsal Root Ganglion Neurons 
Dorsal root ganglia (DRGs) are a collection of primary sensory neural cell bodies. DRG 
neurons are pseudounipolar with a single axon that bifurcates, with one axonal limb 
going to the periphery and one reaching centrally into the spinal cord (Martin, 2005). The 
peripheral axon terminates in the target tissue and has sensory receptors that detect and 
transmit signals along the DRG axon into the spinal cord (Figure 1). Sensory information 
that is initiated by the DRG neuron ultimately is transmitted to the cerebral cortex and 
other central nervous system sites (Martin, 2005, Lumpkin and Caterina, 2007). 
Pain sensing neurons are termed nociceptors, noxious stimulus detectors (Woolf and Ma, 
2007). Nociceptors express specific high threshold (noxious stimulus) sensory 
transducers that are found in the transient receptor potential (TRP) family. Examples of 
high threshold TRPS include TRP vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1). 
TRPV1 is a noxious heat transducer responding to temperatures above 42°C, tissue 
stretching, exogenous compounds such as capsaicin, and endogenous molecules such as 
hydroperoxyeicosatetraenoic acids (HPETEs), hydroxyoctadecadienoic acids (HODEs) 
and leukotrienes (Romac and Liddle, 2012; Alsalem et al., 2014). TRPA1 responds to 
exogenous environmental irritants, such as acrolein or isothiocyanates, and endogenous 
inflammatory molecules, such as 4-hydroxynonenal (4-HNE) and 4-oxononenal (4-ONE) 
(Bautista et al., 2013). Nociceptors also express specific voltage-gated sodium (Nav) ion 
channels, in particular Nav 1.8 (Gold et al., 2003) to promote conduction of unique action 
potentials along the axon from the periphery toward the spinal cord. Furthermore, the 
peripheral nerve terminals of nociceptors have the ability to release neurotransmitters or 
neuromodulators into the innervated tissue (Woolf and Ma, 2007; Miller et al., 2011).  
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Figure 1. Dorsal root ganglia (DRG) neurons are pseudounipolar neurons with a single 
axon that bifurcates. One axonal limb goes to the periphery and one reaches centrally into 
the spinal cord. The peripheral axon terminates in the target tissue, i.e., colon, and has 
sensory receptors that detect and initiate the transmission of signals along the DRG axon 
into the spinal cord. Nociceptors express specific high threshold sensory transducers (red 





Some markers of inflammation, as mentioned above, are heat, redness, and pain and 
occur after nociceptors are stimulated in damaged tissue to release substances that 
produce neurogenic inflammation. Neurogenic inflammation stems from the release of 
pro-inflammatory mediators, such as glutamate, calcitonin gene-related peptide (CGRP), 
and substance P (SP), from nociceptor peripheral nerve terminals. CGRP and SP cause 
blood vessel dilation and increased permeability to produce plasma extravasation and 
inflammatory cell migration and infiltration (Figure 2).  
The underlying mechanisms that produce neurogenic inflammation continue to be under 
investigation. For example, glutamate levels increase in inflamed tissues and initiate 
sensitization of peripheral nerve terminals, producing hyperalgesia and allodynia (Figure 
3; Miller et al., 2011). Hyperalgesia is defined as increased pain from a stimulus that 
normally provokes pain and allodynia is pain due to a stimulus that does not normally 
provoke pain (Classification of Chronic Pain, 1994). Glutamate, released from peripheral 
nerve terminals, stimulates glutamate receptors (GluRs) in an autocrine manner and on 
surrounding nerve terminals (Miller et al., 2011). Antagonism of GluRs on peripheral 
nerve terminals produces pain relief, i.e., reduces hyperalgesia and allodynia, during 
inflammation (Miller et al., 2011). The enzymes, aspartate aminotransferase (AST) and 
glutaminase (GLS), in nerve terminals are important for glutamate synthesis (Figure 4) 
and appear to have important roles in promoting neurogenic inflammation. For example, 
administration of 6-diazo-5-oxo-L-norleucine (DON), a glutaminase inhibitor, during rat 








Figure 2. Noxious stimuli activate transient receptor potentials (TRPs; purple chevron) to 
activate voltage calcium channels (Cav) and allow calcium (Ca
2+) influx into peripheral 
nerve terminals. Calcium influx allows for the vesicular release of glutamate (glu), 
calcitonin gene-related peptide (CGRP), and substance P (SP) to induce neurogenic 
inflammation. CGRP and SP cause blood vessel dilation and increased permeability to 
produce plasma extravasation and inflammatory cell migration and infiltration. Glutamate 
interacts with glutamate receptors (red chevrons, GluRs) to cause peripheral sensitization 











Figure 3. Noxious stimuli activate transient receptor potentials (TRPs; purple chevron) to 
cause vesicular release of glutamate (glu). Glutamate interacts with glutamate receptors 
(GluRs; red chevrons) to cause peripheral sensitization by lowering the threshold of TRPs 
and increasing the activation of voltage gated sodium channels (Nav). Peripheral 
sensitization of peripheral terminals causes hyperalgesia and allodynia. Hyperalgesia is 








Figure 4. Glutamate (glu) is synthesized by two enzymes, glutaminase (GLS) and 
aspartate aminotransferase (AST). GLS converts glutamine (gln) to glutamate, whereas 
AST transaminates aspartate with 2-oxoglutarate (α-ketoglutarate) to produce glutamate 
and oxaloacetate. The tricarboxylic acid cycle (TCA) supplies 2-oxoglurate for the 
production of glutamate. Glutamate is packaged into synaptic vesicles by vesicular 




tissue, and provides pain relief (Hoffman and Miller, 2010, Miller et al., 2011, Miller 
2007). 
Inflammation 
Following neurogenic inflammation, there is a migration of macrophages and 
granulocytes to the site of injury. These cells function in two main roles, as killing cells 
(granulocytes, macrophages) or as amplifiers (macrophages, T cells) of inflammation via 
inflammatory mediators (Hume, 2006). After peripheral trauma, inflammatory mediators 
augment inflammation including an ongoing sensitization of nociceptors, maintaining 
hyperalgesia and allodynia (Birklein and Shmelz, 2008). Some examples include release 
of interkeukin 6 (IL-6), a pro-inflammatory cytokine, from T cells and macrophages that 
is heavily involved in the inflammatory and pain cascades (De Jongh et al., 2003). Local 
and migrating mast cells increase expression and release of mast cell tryptase and 
histamine (Groneberg et al., 2005). The increase of histamine and tryptase into the 
extracellular milieu ultimately results in increased expression and release of tumor 
necrosis factor alpha (TNF-α) in macrophages and other inflammatory cells, which 
further sensitizes nociceptive terminals. Epithelial cells are stimulated to release nerve 
growth factor beta (NGF-β), a neurotrophin that sensitizes nociceptors via the receptors 
Neurotrophin Receptor K1 (NTRK1; also known as TRKA), and Low-Affinity Nerve 
Growth Factor Receptor (LNGFR or p75NTR). After an initial release of NGF-β, epithelial 
cells increase production and exocytosis of NGF-β that is endocytosed by nerve terminals 
and retrogradely transported to DRG cell bodies causing altered protein production, such 





My project was developed out of a desire to better understand the neurogenic component 
underlying the inflammatory process in TNBS-induced colitis. The etiologies of 
inflammatory bowel disease are poorly understood and pain management therapies are 
limited, so this work represents an attempt to gain a deeper understanding of methods that 
may potentially change current practices in the treatment of IBD. Because DON, a GLS 
inhibitor, is known to reduce neurogenic inflammation in a somatic model of 
inflammation (Hoffman and Miller, 2010), I hypothesized that colonic administration of 
DON prior to induction of TNBS colitis would reduce inflammation in the rat colon 
(Figure 5). Three specific aims will address the hypothesis: 
1. DON will reduce TNBS-induced redness and swelling in the colon. Qualitative 
evaluation of the gross morphology of the colon will be used for this aim. 
2. Administration of DON will diminish TNBS-induced leukocyte infiltration, maintain 
epithelial integrity, and preserve nerve fiber interaction with the lamina propria. 
Tinctorial histochemistry and immunohistochemistry will be used to address this aim.  
3. DON will attenuate the increase in pro-inflammatory mediator mRNA during TNBS-
induced colitis. RT-PCR will be used in this aim to evaluate mRNA levels of pro-










Figure 5. 6-diazo-5-oxo-L-norleucine (DON) is a glutamine (GLN) analogue that irreversibly 
inhibits glutaminase (GLS) enzyme. Inhibition of GLS results in decreased synthesis and levels of 
glutamate (GLU) in peripheral nerve terminals. Decreased levels of GLU mitigate neurogenic 
inflammation in peripheral target tissue by reducing extracellular GLU interaction with glutamate 
receptors (GluR, red chevrons). This project will use the application of DON to further determine 








Inflammatory bowel disease (IBD) is characterized by chronic abdominal pain and, in 
some cases, organ pathology (Greenwood-Van Meerveld et al., 2015). It is initiated by a 
traumatic insult inducing acute colitis, i.e., colon inflammation, and, over time, develops 
into a chronic condition due to failure of the inflammatory cascade to self-regulate 
correctly. A key feature of IBD is the large increase in immune cells, granulocytes, and 
pro-inflammatory cytokines. This infiltrate results in an increased expansion of the 
submucosal area. Clinical symptoms of IBD include: inflammation, pain, ulceration, and 
edema, among other unpleasant symptoms (Monavallian-Naeini et al., 2012).  
Colitis and IBD are afflictions that have captured the interest of the medical and scientific 
world for decades because the exact causes are not known and, in most cases, treatment is 
inadequate (Greenwood Van-Meerveld et al., 2015). It has been proposed that instead of 
a single etiology, development of IBD is multifactorial. Dysregulation of the mucosal 
immune system, however, has been strongly implicated as a key factor in the 
pathogenesis of IBD (McCafferty et al.,1994). Despite the large amount of information 
available about this painful disease, there remains much that is unknown. It is of utmost 
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importance, therefore, to determine critical time periods and events in the development of 
this disease to be able to better regulate the pathology.  
We have employed 2,4,6-trinitrobenzene sulfonic acid (TNBS) to provoke colitis in the 
rat colon (Velde et al., 2006). TNBS, dissolved in ethanol, is delivered by intracolonic 
infusion and the epithelial mucosal barrier becomes compromised over time (Randhawa 
et al., 2014). TNBS produces a diffuse inflammation in the distal colon characterized by 
ulceration, edema, leukocyte infiltration, and pro-inflammatory cytokine production (Isik 
et al., 2011; Rogler and Andus, 1998; Mascaraque et al., 2015). Some studies have 
suggested that TNBS-induced colitis has a neurogenic inflammation component (Engel et 
al., 2011). Denervation of the colon or TRPV1 antagonism prior to TNBS-induction 
reduces inflammatory processes in the colon (Takami et al., 2009; Miranda et al., 2007).  
In the current study, a blockade of neurogenic inflammation was attempted by 
interference of the glutamatergic function of colonic peripheral nerve terminals. A 
previous study demonstrated that glutamate receptor antagonism decreased inflammatory 
activation in TNBS-induced colitis (Varga et al., 2010). We employed intracolonic 
pretreatment with DON, a glutaminase inhibitor (Hoffman and Miller, 2010). Previous 
studies in a somatic inflammatory model showed that DON pretreatment decreased 
edema during carrageenan-induced inflammation (Miller et al., 2011). My project, 
therefore, aimed to determine whether pretreatment with DON would mitigate the colonic 
inflammatory effects of TNBS. A variety of methods were used to examine colon 
morphology and determine expression levels of different cytokines. We used histological 
staining to visualize the extent of inflammatory cell infiltrate into the submucosa and 
qualitatively evaluated the results. Immunohistochemistry was employed to better 
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understand how acute inflammation affects the nerve fiber - lamina propria interface. 
Lastly, PCR and Real Time PCR were used to determine RNA levels of pro-
inflammatory cytokines. 
 
Materials and Methods 
Experimental Animals 
6-8 week-old female Sprague-Dawley rats (n=12) weighing between 200-250 g were 
bred and housed in a temperature controlled room with uniform humidity and lighting 
cycles. They had free access to food and water and were placed in plastic cages with wire 
lids and cedar bedding. Four experimental groups were used, with each group containing 
three rats: naïve control, DON-only, TNBS-only, and DON and TNBS. All experimental 
protocols were approved by the Institutional Animal Care and Use Committee at the 
Oklahoma State University Center for Health Sciences.  
 
Administration of 6-Diazo-5-Oxo-l-Norleucine (DON) and Induction of 2,4,6- 
trinitrobenzenesulfonic acid (TNBS) –induced colitis 
Rats were fasted for 24 hours prior to intracolonic infusion with DON. Rats were 
anesthetized with isofluorane (5% induction, 2% maintenance) and 100 µl of DON 
(Sigma-Aldrich, St. Louis, MO) at concentration of 20 µmol/100 µl sterile PBS was 
administered approximately 8 cm into the colon via a disposable catheter attached to a 
1ml syringe. Rats were then placed back in their cages and were fasted for 20 more hours. 
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After 20 hours, rats were anesthetized again with isoflurane and infused with a second 
dose of 100 µl DON. Animals were allowed to recover and, one hour later, the rats were 
anesthetized with isoflurane and infused with 50mg/kg TNBS (Sigma-Aldrich) in 2ml 
50% ethanol. The rats were kept in a Trendelenberg position during and after 
administration of the TNBS to avoid backflow. After infusion, the rats recovered from 
anesthesia and were returned to their cages with food and water. After 24 hours, the rats 
were euthanized with carbon dioxide and exsanguinated. The descending colon was 
excised quickly and processed for further analysis. 
 
Tissue Preparation  
The descending colon was excised, washed in 0.1M phosphate buffer (pH 7.2) and one 
5.0 mm piece was cut and placed in fixative (0.2% paraformaldehyde and 0.8% picric 
acid in 0.1M phosphate buffer, pH 7.2) for morphological studies. The remaining portion 
of the colon was placed in an Eppendorf tube and frozen with liquid nitrogen. The tissue 
was stored at 80°C for later RTPCR processing. 
 
Histological Examination (Immunohistochemistry and Tinctorial Staining) 
The 5.0 mm tissue were removed from the fixative and the gross morphology was 
evaluated for each colon. Representative samples were photographed with a digital 
camera. The pieces were rinsed in phosphate buffered saline (PBS) (pH 7.2) and cut into 
2.0 mm segments. Segments were placed in M-1 Embedding Matrix (Shandon-Lipshaw, 
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Pittsburgh, PA) and snap frozen in liquid nitrogen. The block containing the colon 
segment was placed in a cryostat and 14 μm and 20 μm sections were cut and thaw 
mounted on gel-coated glass slides (Thermo Fisher Scientific, Waltham, MA). The slides 
were placed on a slide warmer at 37°C for 60 minutes to dry the tissue and ensure 
sufficient adherence of the tissue to the slide. 
 
Wright’s Stain (Tinctorial Stain)  
Wright’s stain is a tinctorial, histologic stain of red (eosin) and methylene blue dyes that 
allows for evaluation of white blood cell types. Wright’s stain working solution consisted 
of 0.2 g Wright’s stain powder (Baker, Sanford, ME) in 100 ml methanol (Sigma-
Aldrich) and was filtered before use on the day of experiment. Working solution (1 ml) 
was placed on each slide covering all colon tissues for 1 min. Distilled water (2 ml) was 
added to the undiluted solution on the slides for 2 min. Tissue sections were gently 
washed with running distilled water for up to one minute. Slides were blotted dry and 
observed under a brightfield microscope (Olympus BX51). Microphotographs were taken 
with 10X and 20X objectives using a SPOT RT740 camera (Diagnostic Instruments) and 
stitched together using ImageJ (Mosaic plugin). 
Immunohistochemistry 
A diluent of PBS with 0.3% Triton X-100 (PBS-T) containing 0.15 g of bovine serum 
albumin (BSA) and 0.15 g of polyvinylpyrolidone (PVP) was used for all antiserum 
dilutions. Two groups of slides that were analyzed: VGLUT2 and Peripherin and GLS 
and TRKA. (Table 1)  All sections were incubated with primary antibodies for 16 hours 
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at 4° C. After incubation, the slides were washed in PBS three times for 10 minutes each 
and incubated in secondary antibodies for 1 hour at room temperature. The tissue was 
washed in PBS three times for 10 minutes each cycle and incubated in 300 nm DAPI (for 
nuclear localization) for 15 minutes. Sections were washed in PBS three times for 10 
minutes each. Coverslips were apposed with Prolong Gold mounting medium and stored 
at room temperature in the dark for later analysis. Representative areas of the colon were 
photographed using a fluorescence microscope (Olympus BX51) with 40X objective and 
a SPOT RT740 camera (Diagnostic Instruments).   
Polymerase Chain Reaction and Real Time Polymerase Chain Reaction 
Extraction of total RNA 
Colon samples were thawed and 200 µl of Trizol was added in a sterile Eppendorf tube. 
Tissue was homogenized to extract the total RNA. Another 800 µl of Trizol was added and 
the sample was incubated for 10 minutes at room temperature. After the addition of 0.2 ml 
of chloroform, the samples were vortex mixed and incubated at room temperature for 10 
minutes. Aqueous and organic phase were separated by centrifugation at 12000 g for 10 
minutes at 4°C. The aqueous phase was removed and placed in a sterile Eppendorf tube 
and 0.5 ml of 100% isopropanol was added. The sample was incubated at room temperature 
for 10 minutes and then centrifuged for 15 minutes at 12000 g at 4ºC. The supernatant was 
decanted and the pellet was washed with 1.0 ml of 70% ethanol and vortex agitated. The 
samples were centrifuged for 5 min at 7500 g at 4ºC. The supernatant was removed and the 
pellet was allowed to dry at room temperature for 5-10 minutes. The pellet was resuspended 
in50 µl of RNase-free molecular grade water and incubated at 55-60ºC for 5-10 minutes   
22 
 





Target 1° Antibody 2° Antibody 






















Table 1. Antibodies (Primary & Secondary) and Concentrations. PBS-T with BSA and 
PVP was used for all antiserum dilutions. Two groups were analyzed: VGLUT2 and 
Peripherin or GLS and TRKA. Peripherin labels peripheral sensory nerve axons, whereas 
VGLUT2 and GLS label glutamatergic nerve fibers. TRKA labels NGF responsive nerve 
fibers. All sections were incubated with primary antibodies, followed by washing in PBS 




on a heating block. The total RNA was quantified in a nanodrop spectrophotometer (Table 
2) and the tube stored at -70° C for further analysis 
Synthesis of cDNA (first strand) from extracted mRNA 
We used the total RNA and M-MLV Reverse Transcriptase to synthesize cDNA. Total 














Table 2. The total RNA for the experimental groups was quantified with Nanodrop and 




 Mix 1 (6 µl, Table 3) was added to all the tubes and incubated at 65-70°C for 5 minutes. 
After incubation, the tubes were rapidly chilled on ice and Mix 2 (10 µl, Table 4) added. 
Samples, with a total volume of the 40 µl reaction mixture, were vortexed, followed by 
centrifugation. Samples were incubated according to the following schedule: 15 minutes at 
25°C; 60 minutes at 42°C; 5 minutes at 95°C and stored at 4°C. 
Amplification of cDNA  
The synthesized cDNA was diluted to 20 ng/µl by adding 60 ul deionized water to each 
tube. A master mix was created according to the following table and primers for IL-10, 
p75, GLS, IL-6, TNF-α, NGF-β, and NTRK1 RNA added to each separate tube. (Table 5) 
cDNA (5 µl; 20x5=100 ng cDNA) was placed in each tube, bringing the total volume to 
20 µl. Table 6 contains protocol used to amplify the cDNA fragment.  
Agarose gel electrophoresis of amplified fragment 
An agarose gel (2%) was made in TBE buffer (2.0 g of agarose in 100 ml 1x TBE buffer). 
(Table 7) The liquid was poured into a gel casting tray and allowed to polymerize for at 
least 30-45 minutes with the specific combs. Following polymerization, combs were 
removed and the chamber was filled with 1X TBE buffer. The samples were loaded into 
the wells and the gel run at 170V for 10-15 minutes. Following the run, the gel was stained 


























dNTP 2 µl 
Total 6 µl 
MIX 2  











Total 10 µl 
Master mix  
2x Green Go Taq 
master mix 
10 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
Deionized water 3 µl 
cDNA 5 µl 
Total 20 µl 
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Table 7:  
 
  
Step Temperature/time Cycle(s) 
Denaturation 94ºC/2 min 1 cycle 
Denaturation 94ºC/15 sec  
Annealing 55ºC/15 sec  
Extension 68ºC/15 sec 30 cycles 
Final extension 72ºC/5 min 1 cycle 
End 4ºC  
TBE buffer 10x/1L 
Tris-HCl 108 g 
Boric acid 55 g 
EDTA (0.5M,  
pH 8.0) 
40 ml 
Adjust the volume to 1000 ml 
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Table 3. 6 µl of Mix 1 was added to all the tubes and incubated at 65-70°C for 5 minutes.  
Table 4. After incubation, the tubes were chilled on ice and 10 µl of Mix 2 added. Samples 
were mixed with vortex agitation, followed by centrifugation. 
Table 5. A master mix was prepared and primers for IL-10, p75, GLS, IL-6, TNF-α, NGF-
β, and NTRK1 RNA added to each separate tube. 5.0 µl of cDNA was placed each tube, 
bringing the total volume to 20 µl.  
Table 6. The amplification of the cDNA of IL-10, p75, GLS, IL-6, TNF-α, NGF-β, and 
NTRK1 was carried out in a thermocycler.  
Table 7. The TBE buffer was prepared in a manner to preclude DNA deprotonation and 
nucleic acids degradation. The slightly basic conditions of the Tris-HCl buffer keeps DNA 
deprotonated and soluble in water. EDTA is a chelator of divalent cations and functions to 





Real Time PCR of IL-10, p75, GLS, IL-6, TNF-α, NGF-β, and NTRK1 at 24 Hours 
Quantitative real-time PCR was used to measure IL-10, p75, GLS, IL-6, TNF-α, NGF-β, 
and NTRK1 mRNA transcription. After completing the thermocycler program, 
messenger RNA (mRNA) levels were measured from the colon at 24 hours and melt 
curves and threshold cycle (Ct) data generated. The cytokine and neutrophin expression 
level of rat colon was normalized with that of rat β-actin mRNA. Primers used for RT-q 




At 24 hours after rectal administration of TNBS, the gross morphology of the colon 
showed considerable inflammation and swelling compared to colons from naïve rats 
(Figure 6). The colons from the DON+TNBS group had less swelling and inflammation 
compared to TNBS treated colons, but was more distended than the control colons 
(Figure 6). The DON treated colons remained relatively unchanged when compared to 









Figure 6: Gross morphology of experimental colons 
 
  
Control DON+TNBS TNBS 
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Figure 6. The colon on the left came from the control group. This group received no 
treatment of any kind. The tissue sample in the middle is from a DON+TNBS rat. There 
is some visible swelling and inflammation. The colon on the right is from the TNBS 
treated rat. There is obvious redness and swelling present in this section caused by 




Wright’s Stain  
Under microscopic evaluation, there was no histological damage to the naïve control 
group (Figure 7A). In the TNBS group, the epithelium sustained severe damage and 
thinning (Figure 7C). There was edema and transmural inflammation present in all TNBS 
treated animals, with the presence of granulomas and submucosal granulocyte permeation 
(Figure 7C). Additionally, the lumen was noticeably larger than the lumen from the 
control group (Figure 7C). In the DON+TNBS group, the colon sections were edematous 
and had some submucosal infiltration by granulocytes, however not to the extent as the 
TNBS treated colons (Figure 7D). The DON-only colons appeared similar to control with 
a slight thickening of the submucosa (Figure 7B).  
 
Immunohistochemistry 
We stained for two groups: Peripherin + VGLUT2 and GLS + TRKA. In the Peripherin + 
VGLUT2 group, the nerve fibers were labeled with a green fluorophore for VGLUT2 and 
the peripherin was labeled with a red fluorophore (Figure 8). In the control, we saw intact 
crypts and nearby nerve fibers interacting with cells of the lamina propria. DON only 
sections were similar to the control. The TNBS group had an unstructured epithelial layer 
with degraded crypts. Nerve fibers in the lamina propria interacted with granulocytes and 
were in close proximity to the lumen. The DON + TNBS had light epithelial loss, but in 
most cases the damage was slight. Nerve fibers in lamina propria were comparable to 












Figure 8: Immunohistochemical labeling of VGLUT2 and Peripherin A 
 








Figure 7. Groups are labeled as follows: Control (A), DON (B), TNBS, (C), DON+TNBS 
(D). There was no histological damage to the naïve group and little damage to the DON 
group. In the TNBS group, the epithelium sustained severe damage and the colon was 
edematous and inflamed with the presence of granulomas and submucosal granulocytic 
permeation. The lumen was larger than the control lumen. In the DON+TNBS group, the 
colon was edematous with some submucosal infiltration by granulocytes. The DON colon 
was similar in appearance to control, but the submucosa was slightly thicker. 
 
Figure 8. Groups are labeled as follows: Control (A), DON (B), TNBS, (C), DON+TNBS 
(D) with Peripherin (red) + VGLUT2 (green). In controls and DON only colon sections, 
there were intact crypts and nerve fibers were in close contact with lamina propria cells. 
The TNBS colon had an unstructured epithelial layer and degraded crypts. The lamina 
propria had granulocyte infiltration and nerve fibers appear to interact with granulocytes. 






β-actin was used as a loading control for RTPCR experiments and levels of β-actin 
remained constant in all experimental groups. In the TNBS group, there was a noticeable 
increase in IL-6, TNF-α, NGF-β, and NTRK1 mRNA as compared to the control. The 
DON+TNBS group had attenuated levels IL-6, TNF-α, NGF-β, and NTRK1 mRNA 
compared to the TNBS treated group. The DON group was similar to the naïve control 
group in mRNA levels for IL-6, TNF-α, NGF-β, and NTRK1. (Figures 9, 10, 11) 
Discussion 
There has been an increase in interest from researchers searching for various methods 
that may be used to treat IBD. The TNBS model provides a consistent colitis in rats and 
may be used to evaluate treatments for IBD in humans. In rats, TNBS is administered 
rectally and slowly disrupts the epithelium. This method has been commonly used to 
study the effects of IBD in an animal model (Morris et al., 1989) and TNBS 
administration results in symptoms that closely mimic characteristics of IBD in humans 
(Blumberg et al., 1999). Acute TNBS colitis is induced by T-helper 1 (Th1) cell response 
and propagated by release of Th1 and Th2 cytokine release (Dohi and Fujihashi, 2006). 
Our study was designed to determine if GLS inhibition with 6-diazo-5-oxo-L-norleucine 
(DON) would have anti-inflammatory properties. When TNBS was administered rectally, 
there was considerable macroscopic inflammation and swelling in the colon, a change 
consistent with previous descriptions (Motavallian-Naeini et al., 2012). Microscopically, 
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 Figure 10: Relative expression of pro-inflammatory cytokines and 
























Figure 9. In the TNBS group, mRNA levels of IL-6, NTRK1, and TNF-α show a 
dramatic increase qualitatively. NGF-β mRNA levels increase slightly as compared to 
control levels, but the difference between groups is not as pronounced as with other 
mRNAs. β-actin mRNA was used as a loading control. 
 
Figure 10. Quantitative evaluation of single RTPCR blots. All graphs illustrate an 
increase in mRNA for inflammatory cytokines, neurotrophins, or neurotrophic receptors 
in the TNBS group compared to controls. In the DON+TNBS group, there is a marked 
decrease in mRNA levels compared to TNBS alone. Relative expression of mRNAs for 
the control and DON groups are similar in all graphs. The IL-6 graph shows an almost 6-
fold increase in the TNBS group compared DON+TNBS group and 8-fold increase 
compared to Control and DON groups. There is also a 3-fold increase in IL-6 mRNA in 
DON+TNBS group compared to and DON and Control. TNBS doubles mRNA for TNF-
α, NGF-β, and NTRK1 compared to Control and DON groups and this alteration is 
attenuated in the DON+TNBS group. 
 
Figure 11. Real-time RTPCR. A comparison of fold expression of IL-6 mRNA shows 
that there is a significant elevation in TNBS groups and DON+TNBS attenuates this 




An increase in edema and infiltration of submucosal granulocytes was also observed. 
Analyses of the pro-inflammatory proteins revealed greater levels of pro-inflammatory 
mediators and their receptors. The DON served as a protective agent and reduced the 
amount of swelling and redness.  As was previously mentioned, DON is a glutaminase 
inhibitor that plays a role in decreasing inflammation by affecting the activity of 
peripheral neuronal fibers. The TNBS initiates neurogenic inflammation, which drives 
the development and persistence of colitis. DON acts upon the nerve fibers to reduce 
neuronal activity and thus, reduce inflammation. Similar studies have examined this 
phenomenon in a somatic model or with different pharmacotherapies (Hoffman and 
Miller, 2010; McCafferty et al., 1994), however, this work is novel in that RNA 
expression of inflammatory mediators in the inflamed colon at 24 hours has not 
previously been studied.  
When TNBS is initially administered, the ethanol immediately begins to degrade the 
epithelium exposing the mucosa to luminal antigen. Although the etiology of induced 
IBD is not fully understood, there is work that suggests that the robust response is due to 
the mucosal immune system’s failure to familiarize itself with luminal antigens 
(Brandtzaeg et al., 1997). An alternate hypothesis proposed that the pathology is due to 
Th cells that fail to regulate cytokine levels resulting in an inflammatory response (Bouma 
and Strober, 2003). Regardless of the etiology, colonic infusion resulting in inflammation 
bears striking similarities to inflammatory bowel disease. The increase in the amount of 
macrophages and neutrophils present in the submucosa also seem to contribute to the 
symptoms seen in colitis. Macrophages produce cytokines such as IL-6 and TNF-α, 
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which may induce various factors that function to disrupt the extracellular matrix and 
vessel walls (MacDonald and Murch, 1994).  
Colitis is the result of chronic inflammation in the colon and is accompanied by pain and 
discomfort. Pain and inflammation are often seen together after an injury is sustained, 
therefore, reducing inflammation will also reduce or relieve pain. Abdominal pain is a 
common cause for seeking medical attention; however, methods of treatment are mostly 
inefficient and usually are accompanied by many unpleasant side effects (Greenwood 
Van-Meerveld et al., 2015). In many cases, the pain goes beyond simple discomfort and 
enters the realm of crippling pain. This high incidence of visceral pain has resulted in an 
interest in methods of relieving pain and inflammation in IBD. A deeper understanding of 
the etiology of the disease has the potential to reveal better methods of prophylaxis and 
therapy. Additionally, determining what compounds can be utilized to provide anti-
inflammation and pain relief will allow for more efficacious chemotherapy of patients 
who are afflicted with this disease. 
In the future, we hope to better understand the course of IBD by studying it at various 
time points and by studying the effects of DON administration at different points. 
Another possible direction is the analysis of pain felt by the animal with and without the 
protective effects of DON and by analyzing this over a period of time. This study served 
as a stepping stone for future work that we expect will further explore inflammatory 










We hypothesized that administration of DON prior to colonic infusion of TNBS will 
reduce inflammation in the rat colon. Our results lead us to accept the hypothesis by 
virtue of the decrease in edema, pro-inflammatory cell infiltration, and epithelial damage 
seen in colons that had been pre-treated with DON. Aim 1 was to determine decreased 
redness and swelling in the colons of rats that received treatment with DON. This was 
seen macroscopically when analyzing gross morphology of the colons; there was a visible 
difference between the appearances of colons in different experimental groups. We also 
saw a decline in pro-inflammatory cytokine expression in rats who received DON. The 
RNA levels were significantly reduced in the DON + TNBS group when compared to the 
TNBS group. Finally, administration of DON resulted in less pro-inflammatory cell 
infiltration and a preservation of nerve fiber interaction with the lamina propria. Also, the 
structures of the crypts in the DON+TNBS group were preserved, unlike those of the 
TNBS group. In this experimental group, there was severe degradation of the structure of 
the epithelium and crypts. 
In the future, we hope to better understand the course of IBD by studying it at various 
time points. This will serve to give us a more in-depth understanding of the inflammatory 
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process by allowing us to study cytokine and neurotrophin profiles to determine what 
compounds are present and active in the inflamed area. Repeating this experiment at 
longer intervals will also allow us to study the effects of DON administration at different 
points. It is possible that the effects of DON are different depending on what point the 
animal is in the development of colitis. 
We did not study nociception in this project; however, it would be a valid addition to a 
future study. A possible future direction is the analysis of inflammation-induced 
nociception felt by the animal after induction of TNBS. It would be worthwhile to 
determine how pain levels change with and without the protective effects of DON 
administration. This could also be further expanded by studying effects of DON on 
nociception over a period of time and at various time points. Finally, a future study that 
involves examination of changes in protein levels and determination of the time 
difference between expression of protein and its corresponding RNA would yield a 
wealth of information about the time line of the development of colitis. This study served 
as a stepping stone for future work that we expect will further explore inflammatory 
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